<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Zileuton</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00744</strong>&#160; (APRD00265)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational, withdrawn</td></tr><tr><th>Description</th><td><p>Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00744/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00744/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00744.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00744.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00744.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00744.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00744.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00744">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Leutrol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Zileuton</td><td>German</td><td>INN</td></tr><tr><td>Zileuton</td><td>French/Spanish</td><td>INN</td></tr><tr><td>Zileutonum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Zyflo</td><td>Cornerstone</td></tr><tr><td>Zyflo CR</td><td>Cornerstone</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li>
<li><a href="/mesh/lipoxygenase-inhibitors">Lipoxygenase Inhibitors</a></li>
<li><a href="/mesh/leukotriene-antagonists">Leukotriene Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>111406-87-2</td></tr><tr><th>Weight</th><td>Average: 236.29<br>Monoisotopic: 236.061948328</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>MWLSOWXNZPKENC-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzothiophenes</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzothiophenes</td></tr><tr><th>Alternative parents</th><td>Benzene and Substituted Derivatives; Thiophenes; Polyamines</td></tr><tr><th>Substituents</th><td>benzene; thiophene; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzothiophenes. These are organic compounds containing a benzene fused to a thiepine ring (a five-member ring with six carbon atoms and one sulfur atom).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.</td></tr><tr><th>Pharmacodynamics</th><td>Zileuton is an asthma drug that differs chemically and pharmacologically from other antiasthmatic agents. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway. Current data indicates that asthma is a chronic inflammatory disorder of the airways involving the production and activity of several endogenous inflammatory mediators, including leukotrienes. Sulfido-peptide leukotrienes (LTC4, LTD4, LTE4, also known as the slow-releasing substances of anaphylaxis) and LTB4, a chemoattractant for neutrophils and eosinophils, are derived from the initial unstable product of arachidonic acid metabolism, leukotriene A4 (LTA4), and can be measured in a number of biological fluids including bronchoalveolar lavage fluid (BALF) from asthmatic patients. In humans, pretreatment with zileuton attenuated bronchoconstriction caused by cold air challenge in patients with asthma.</td></tr><tr><th>Mechanism of action</th><td>Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in <i>in vitro</i> systems. Due to the role of leukotrienes in the pathogenesis of asthma, modulation of leukotriene formation by interruption of 5-lipoxygenase activity may reduce airway symptoms, decrease bronchial smooth muscle tone, and improve asthma control.</td></tr><tr><th>Absorption</th><td>Rapidly and almost completely absorbed. The absolute bioavailability is unknown.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1.2 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>93% bound to plasma proteins, primarily to albumin.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Zileuton and its N-dehydroxylated metabolite are oxidatively metabolized by the cytochrome P450 isoenzymes 1A2, 2C9 and 3A4.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Zileuton</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li></ul></td><td><a href="/metabolites/DBMET00138">Hydroxyzileuton</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/138">Details</a></td></tr><tr><td>Zileuton</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00139">Zileuton sulfoxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/139">Details</a></td></tr><tr><td>Zileuton</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000017" target="_blank">Prostaglandin G/H synthase 1</a></li></ul></td><td><a href="/metabolites/DBMET00140">Dehydroxyzyleuton</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/140">Details</a></td></tr><tr><td>Zileuton</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003538" target="_blank">UDP-glucuronosyltransferase 1-9</a></li></ul></td><td><a href="/metabolites/DBMET00141">Zileuton O-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/141">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00140">Dehydroxyzyleuton</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET01255">Dehydroxyzileuton sulfoxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1412">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Elimination of zileuton is predominantly via metabolism with a mean terminal half-life of 2.5 hours. 
The urinary excretion of the inactive N-dehydroxylated metabolite and unchanged zileuton each accounted for less than 0.5% of the dose.</td></tr><tr><th>Half life</th><td>2.5 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>Apparent oral cl=7 mL/min/kg</li>
</ul></td></tr><tr><th>Toxicity</th><td>The oral minimum lethal doses in mice and rats were 500-4000 and 300-1000 mg/kg in various preparations, respectively (providing greater than 3 and 9 times the systemic exposure [AUC] achieved at the maximum recommended human daily oral dose, respectively).</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9915</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8846</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5793</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6789</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9684</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9765</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9583</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.5907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6384</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5318</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7975</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6451</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7062</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5821</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.5865
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7968
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.985
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2646 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9884
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9051
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Cornerstone therapeutics inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.cpsrx.com">Cornerstone Pharmacy</a></li>
<li>Critical Therapeutics Inc.</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Zileuton increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine. </td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. </td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Zileuton increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00980">Ramelteon</a></td><td>Zileuton increases levels/toxicity of ramelteon</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Zileuton may increase the therapeutic and adverse effects of theophylline by increasing its serum concentration. Monitor for changes in the therapeutic and adverse effects of theophylline if zileuton is initiated, discontinued or dose changed. Dose alterations should be considered.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>